Axinn Granted Summary Judgment in Delaware Federal Court
June 24, 2014
Law360
A Delaware federal judge on June 24 granted summary judgment to Axinn client Alvogen in a lawsuit brought by Novartis AG over a generic version of the Exelon dementia treatment patch. After the close of fact discovery, Novartis granted a covenant not to sue to Alvogen.
Click here to read about the judgment in Law360’s article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Informa 34th Annual Advanced EU Brussels Conference
Speaking Engagement
Antitrust
Kisaco Research Pharma and Biotech Patent Litigation Summit 2025
Speaking Engagement
Intellectual Property
GCR Live: Women in Antitrust 2025
Speaking Engagement
Antitrust
Global Legal Group Global Class Actions Symposium 2025
Speaking Engagement
Litigation & Trials
ITCTLA Mock Hearing Program 2025
Speaking Engagement
Intellectual Property
ALM General Counsel Conference East 2025
Speaking Engagement
Antitrust
Axinn Recognized in Thirteen Categories of 2026 “Best Law Firms” Report
Awards & Recognitions
Antitrust
Mastering Multi-Jurisdictional Mergers: Strategies for Navigating Complex Global Antitrust Reviews
Byline Articles
Antitrust
The Government Shutdown’s Impact on Antitrust
Axinn Viewpoints
Antitrust
NAPABA Convention 2025
Sponsorship
Antitrust
